{"id":72428,"date":"2026-08-13T11:57:48","date_gmt":"2026-08-13T03:57:48","guid":{"rendered":"https:\/\/flcube.com\/?p=72428"},"modified":"2026-08-13T11:57:49","modified_gmt":"2026-08-13T03:57:49","slug":"impact-therapeutics-nominates-kat6a-specific-protac-imp2794-as-preclinical-candidate-from-proprietary-tpd-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72428","title":{"rendered":"IMPACT Therapeutics Nominates KAT6A-Specific PROTAC IMP2794 as Preclinical Candidate From Proprietary TPD Platform"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>IMPACT Therapeutics, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/7630:HKG\">HKG: 7630<\/a>) announced the nomination of <strong>IMP2794<\/strong> as a <strong>preclinical candidate (PCC)<\/strong> \u2014 a highly <strong>KAT6A-specific PROTAC<\/strong> (Proteolysis Targeting Chimera) and the first candidate discovered from the company&#8217;s <strong>proprietary targeted protein degradation platform<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-research-milestone\" class=\"wp-block-heading\">Research Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>IMPACT Therapeutics, Inc. (HKG: 7630)<\/td><\/tr><tr><td><strong>Event<\/strong><\/td><td>Nomination of preclinical candidate (PCC)<\/td><\/tr><tr><td><strong>Candidate<\/strong><\/td><td>IMP2794<\/td><\/tr><tr><td><strong>Modality<\/strong><\/td><td>PROTAC (Proteolysis Targeting Chimera)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>KAT6A (highly specific)<\/td><\/tr><tr><td><strong>Selectivity<\/strong><\/td><td>Over 1,000-fold selectivity versus KAT6B<\/td><\/tr><tr><td><strong>Platform<\/strong><\/td><td>IMPACT Therapeutics&#8217; proprietary targeted protein degradation platform<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>13 Aug 2026<\/td><\/tr><tr><td><strong>Milestone Significance<\/strong><\/td><td>First PCC generated from the platform<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-preclinical-profile-imp2794\" class=\"wp-block-heading\">Preclinical Profile \u2013 IMP2794<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Potency &amp; Selectivity:<\/strong> A potent and selective <strong>KAT6A degrader<\/strong> with over 1,000-fold selectivity against KAT6B \u2014 a critical distinction, as inhibition of KAT6B is associated with potential hematopoietic toxicities<\/li>\n\n\n\n<li><strong>In Vitro:<\/strong> Displays potent cytotoxic activity against tumor cells with minimal hematopoietic toxicity<\/li>\n\n\n\n<li><strong>In Vivo:<\/strong> Demonstrates significant antitumor efficacy in <strong>breast cancer CDX models<\/strong><\/li>\n\n\n\n<li><strong>Pharmacokinetics:<\/strong> Achieves remarkably high <strong>oral bioavailability across multiple animal species<\/strong>, indicating strong potential for optimal human systemic exposure<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-target-rationale-kat6a\" class=\"wp-block-heading\">Target Rationale \u2013 KAT6A<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Expression:<\/strong> KAT6A is highly expressed in various cancers, particularly in <strong>estrogen receptor-positive (ER+) breast cancer<\/strong><\/li>\n\n\n\n<li><strong>Selectivity Challenge:<\/strong> Traditional small-molecule inhibitors struggle to achieve selective KAT6A targeting because of the homolog KAT6B, whose inhibition carries hematopoietic toxicity risk<\/li>\n\n\n\n<li><strong>PROTAC Advantage:<\/strong> Molecules such as IMP2794 enable <strong>selective and tunable degradation of previously &#8220;undruggable&#8221; targets<\/strong>, broadening the therapeutic window and reducing toxicity<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Validation:<\/strong> IMP2794 is the <strong>first PCC<\/strong> from IMPACT Therapeutics&#8217; TPD platform, validating the company&#8217;s degrader discovery engine and establishing a template for subsequent programs.<\/li>\n\n\n\n<li><strong>Undruggable Target Opportunity:<\/strong> The nomination adds IMPACT Therapeutics to the growing cohort of companies pursuing PROTACs against targets that resist conventional inhibition, one of drug discovery&#8217;s most active frontiers.<\/li>\n\n\n\n<li><strong>ER+ Breast Cancer Focus:<\/strong> With KAT6A highly expressed in ER+ breast cancer, the candidate is positioned against a large, commercially established oncology segment.<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> IND-enabling studies and timelines toward first-in-human trials were not disclosed.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the preclinical development potential of IMP2794. Actual results may differ due to risks including IND-enabling progress, toxicology outcomes, and competitive dynamics in targeted protein degradation.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026081200719_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026081200719_c.\"><\/object><a id=\"wp-block-file--media-e677ac66-36b6-4267-8db6-9937a3637920\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026081200719_c.pdf\">2026081200719_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026081200719_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e677ac66-36b6-4267-8db6-9937a3637920\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>IMPACT Therapeutics, Inc. (HKG: 7630) announced the nomination of IMP2794 as a preclinical candidate (PCC)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[4765,961,70],"class_list":["post-72428","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-hkg-7630","tag-impact-therapeutics","tag-tpd"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>IMPACT Therapeutics Nominates KAT6A-Specific PROTAC IMP2794 as Preclinical Candidate From Proprietary TPD Platform - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"IMPACT Therapeutics, Inc. (HKG: 7630) announced the nomination of IMP2794 as a preclinical candidate (PCC) \u2014 a highly KAT6A-specific PROTAC (Proteolysis Targeting Chimera) and the first candidate discovered from the company&#039;s proprietary targeted protein degradation platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72428\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IMPACT Therapeutics Nominates KAT6A-Specific PROTAC IMP2794 as Preclinical Candidate From Proprietary TPD Platform\" \/>\n<meta property=\"og:description\" content=\"IMPACT Therapeutics, Inc. (HKG: 7630) announced the nomination of IMP2794 as a preclinical candidate (PCC) \u2014 a highly KAT6A-specific PROTAC (Proteolysis Targeting Chimera) and the first candidate discovered from the company&#039;s proprietary targeted protein degradation platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72428\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-13T03:57:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-13T03:57:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72428#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72428\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"IMPACT Therapeutics Nominates KAT6A-Specific PROTAC IMP2794 as Preclinical Candidate From Proprietary TPD Platform\",\"datePublished\":\"2026-08-13T03:57:48+00:00\",\"dateModified\":\"2026-08-13T03:57:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72428\"},\"wordCount\":381,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 7630\",\"Impact Therapeutics\",\"TPD\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72428#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72428\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72428\",\"name\":\"IMPACT Therapeutics Nominates KAT6A-Specific PROTAC IMP2794 as Preclinical Candidate From Proprietary TPD Platform - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-13T03:57:48+00:00\",\"dateModified\":\"2026-08-13T03:57:49+00:00\",\"description\":\"IMPACT Therapeutics, Inc. (HKG: 7630) announced the nomination of IMP2794 as a preclinical candidate (PCC) \u2014 a highly KAT6A-specific PROTAC (Proteolysis Targeting Chimera) and the first candidate discovered from the company's proprietary targeted protein degradation platform.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72428#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72428\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72428#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IMPACT Therapeutics Nominates KAT6A-Specific PROTAC IMP2794 as Preclinical Candidate From Proprietary TPD Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"IMPACT Therapeutics Nominates KAT6A-Specific PROTAC IMP2794 as Preclinical Candidate From Proprietary TPD Platform - Insight, China&#039;s Pharmaceutical Industry","description":"IMPACT Therapeutics, Inc. (HKG: 7630) announced the nomination of IMP2794 as a preclinical candidate (PCC) \u2014 a highly KAT6A-specific PROTAC (Proteolysis Targeting Chimera) and the first candidate discovered from the company's proprietary targeted protein degradation platform.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72428","og_locale":"en_US","og_type":"article","og_title":"IMPACT Therapeutics Nominates KAT6A-Specific PROTAC IMP2794 as Preclinical Candidate From Proprietary TPD Platform","og_description":"IMPACT Therapeutics, Inc. (HKG: 7630) announced the nomination of IMP2794 as a preclinical candidate (PCC) \u2014 a highly KAT6A-specific PROTAC (Proteolysis Targeting Chimera) and the first candidate discovered from the company's proprietary targeted protein degradation platform.","og_url":"https:\/\/flcube.com\/?p=72428","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-13T03:57:48+00:00","article_modified_time":"2026-08-13T03:57:49+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72428#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72428"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"IMPACT Therapeutics Nominates KAT6A-Specific PROTAC IMP2794 as Preclinical Candidate From Proprietary TPD Platform","datePublished":"2026-08-13T03:57:48+00:00","dateModified":"2026-08-13T03:57:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72428"},"wordCount":381,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 7630","Impact Therapeutics","TPD"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72428#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72428","url":"https:\/\/flcube.com\/?p=72428","name":"IMPACT Therapeutics Nominates KAT6A-Specific PROTAC IMP2794 as Preclinical Candidate From Proprietary TPD Platform - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-13T03:57:48+00:00","dateModified":"2026-08-13T03:57:49+00:00","description":"IMPACT Therapeutics, Inc. (HKG: 7630) announced the nomination of IMP2794 as a preclinical candidate (PCC) \u2014 a highly KAT6A-specific PROTAC (Proteolysis Targeting Chimera) and the first candidate discovered from the company's proprietary targeted protein degradation platform.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72428#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72428"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72428#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"IMPACT Therapeutics Nominates KAT6A-Specific PROTAC IMP2794 as Preclinical Candidate From Proprietary TPD Platform"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72428","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72428"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72428\/revisions"}],"predecessor-version":[{"id":72432,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72428\/revisions\/72432"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}